Atrium Therapeutics, Inc. (RNA) SEC Filings & Earnings Calls
EquiReason read 8 Atrium Therapeutics, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-08 — Atrium Therapeutics entered a securities purchase agreement for a ~$50M PIPE offering of common stock and pre-funded warrants, with proceeds to fund operations through 2028..
Source: SEC EDGAR filings · read by EquiReason
- Market cap
- 140.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
8 Oct 20268-K · 1.01, 3.02, 8.01Atrium Therapeutics entered a securities purchase agreement for a ~$50M PIPE offering of common stock and pre-funded warrants, with proceeds to fund operations through 2028.open
Figures in the filing · each found in the filing text
| gross proceeds · Q4-2026 | $50M | |
| shares outstanding post-offering · Q4-2026 | 22,276,027 |
Risks flagged
Dilution risk from new shares and warrants; potential overhang on stock price.
“Issuance of 5.17M shares and 1.13M pre-funded warrants; post-offering share count 22.3M.”
13 Aug 20268-K · 2.02Collaboration Revenue $3M; R&D Expenses $15M; G&A Expenses $10Mearningsopen
Figures in the filing · each found in the filing text
| Collaboration Revenue · Q2-2026 | $3M | |
| R&D Expenses · Q2-2026 | $15M | |
| G&A Expenses · Q2-2026 | $10M | |
| Cash, Cash Equivalents and Short-term Investments · Q2-2026 | $264M |
Risks flagged
Clinical trial execution risk for ATR 1072 and pipeline dependency.
“First participant enrollment expected by end of 2026; initial data in H2 2027.”
13 Aug 202610-QAtrium Therapeutics reported Q2 2026 results as a newly independent company, with net loss widening to $20.2M from $12.9M in Q2 2025, driven by higher G&A and R&D expenses post-spin-off.earningsopen
Figures in the filing · each found in the filing text
| Collaboration revenue · Q2-2026 | $3M | -22% y/y |
| Net loss · Q2-2026 | $-20M | +57% y/y |
| Research and development expense · Q2-2026 | $15M | +15% y/y |
| General and administrative expense · Q2-2026 | $10M | +201% y/y |
| Cash and cash equivalents · 2026-06-30 | $72M | |
| Short-term investments · 2026-06-30 | $192M | |
| Deferred revenue · 2026-06-30 | $43M | -20% y/y |
| Stock-based compensation expense · H1-2026 | $13M | +350% y/y |
Risks flagged
Early-stage development risk
“The Company has incurred recurring losses since its inception and expects to continue to generate operating losses for the foreseeable future.” · word for word
Dependence on collaborations
“Revenue from R&D services performed in satisfaction of the performance obligation under the BMS Collaboration Agreement is $3.0 million and $3.8 million for the three months ended June 30, 2026 and 2025, respectively.” · word for word
Intellectual property dependency on former parent
“a substantial portion of the intellectual property and data material to the Company’s cardiology programs is owned by Avidity and remains subject to certain existing third‑party obligations.” · word for word
14 Jul 20268-K · 8.01FDA cleared IND for ATR 1072 Phase 1/2 trial in PRKAG2 syndrome, enabling clinical advancement.open
Risks flagged
Early-stage clinical trial; high risk of failure.
“Phase 1/2 trial; no efficacy data yet.”
14 May 202610-QCollaboration revenue $20M; Net loss $-17M; Cash and cash equivalents $268Mopen
Figures in the filing · each found in the filing text
| Collaboration revenue · Q1-2026 | $20M | |
| Net loss · Q1-2026 | $-17M | |
| Cash and cash equivalents · 2026-03-31 | $268M | |
| Research and development expense · Q1-2026 | $17M | |
| General and administrative expense · Q1-2026 | $20M |
Risks flagged
Pre-clinical stage; no approved products
“We are a pre-clinical stage biopharmaceutical company focused on developing the delivery of ribonucleic acid ("RNA") therapeutics to the heart muscle for people living with cardiomyopathies.”
Dependence on collaborations for revenue
“The Company recognized revenue of $19.6 million and $1.6 million for the three months ended March 31, 2026 and 2025, respectively, solely related to the BMS Collaboration Agreement.”
Intellectual property dependency on former parent
“Avidity retained all intellectual property and data that were not exclusively related to cardiology, except for certain platform‑related intellectual property that will initially be owned by the Company, subject to Avidity’s right to obtain an assignment of such intellectual property and to grant back a license to the Company.” · word for word
14 May 20268-K · 2.02Collaboration revenue $20M; R&D expenses $17M; G&A expenses $20Mearningsopen
Figures in the filing · each found in the filing text
| Collaboration revenue · Q1-2026 | $20M | |
| R&D expenses · Q1-2026 | $17M | |
| G&A expenses · Q1-2026 | $20M | |
| Cash and cash equivalents · Q1-2026 | $268M |
Risks flagged
Early-stage company with no approved products; high cash burn.
“R&D and G&A expenses total $37M; no product revenue.”
27 Feb 20268-K · 1.01, 5.01, 5.02Avidity Biosciences completed separation of early-stage precision cardiology programs into Atrium Therapeutics, distributing shares to Avidity stockholders; Atrium became independent public company trading under RNA.open
Risks flagged
Newly independent company with no revenue; early-stage pipeline risk.
“Company became an independent public company... early stage precision cardiology programs”
26 Feb 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen
Risks flagged
Early-stage pipeline risk; no approved products or revenue; reliance on collaborations and future development.
“Company assets are early-stage precision cardiology programs (ATR1086, ATR1072) targeting rare genetic cardiomyopathies.”
Atrium Therapeutics, Inc. — questions
- What did Atrium Therapeutics, Inc. file recently?
- 8 SEC filings in the last 12 months. Latest: 8-K on 2026-10-08 — Atrium Therapeutics entered a securities purchase agreement for a ~$50M PIPE offering of common stock and pre-funded warrants, with proceeds to fund operations through 2028.
Every figure on this page comes from Atrium Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.